Navigation Links
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
Date:9/19/2011

SAN DIEGO, and PHILADELPHIA, Sept. 19, 2011 /PRNewswire/ -- Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA™, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.  These data were presented at the American Society for Bone and Mineral Research 2011 Annual Meeting by ORACAL investigator Neil Binkley, MD, who is an Associate Professor of Endocrinology and Geriatrics at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin.

The ORACAL study was a Phase III multinational, randomized, double-blind, double-dummy, placebo controlled trial of Tarsa's oral recombinant salmon calcitonin compared to placebo and to commercially available, synthetic salmon calcitonin administered by nasal spray.  The trial enrolled 565 postmenopausal women in six countries with established osteoporosis.

Earlier this year, Tarsa reported top-line efficacy and safety results from the ORACAL trial.  The data reported today show that OSTORA achieved all of the efficacy endpoints in the trial and indicate that the safety profile of OSTORA did not substantially differ from nasal calcitonin or placebo.  The majority of adverse events were mild or moderate, and OSTORA was also significantly less immunogenic than nasal calcitonin spray.  

"These are encouraging results that may be of particular relevance for the women with osteoporosis who are reluctant to take or unable to tolerate currently available treatments," said Dr. Binkley.  "Potential safety issues with current drug therapies, while rare, have led some osteoporosis patients to discontinue therapy or avoid beginning treatment.  Calcitonin has a long history of safety for postmenopausal osteoporosis treatment, and potential availability of this once-daily oral formulation could make it a useful new option
'/>"/>

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
2. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
3. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
4. Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
8. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
9. Nile Therapeutics to Present at Rodman & Renshaw Global Investment Conference
10. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
11. Global Sepsis Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ROSEMONT, Ill. , Aug. 3, 2015 ... ankle problem, and you,re looking for the best possible ... for the best outcome too, and now there,s a ... there. Following steps recommended by the American Orthopaedic ... after surgery can help you avoid complications and heal ...
(Date:8/3/2015)... 3, 2015 ReportsnReports.com adds ... with 2020 forecasts as well as Global Medical ... devices intelligence collection of its library. ... 2020 forecasts spread across 164 pages, talking about ... and figures is now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html ...
(Date:8/3/2015)... BUFFALO, N.Y. , Aug. 3, 2015 /PRNewswire/ ... the Wilmot Cancer Institute to the OmniSeq SM ... from Roswell Park Cancer Institute (RPCI) and announced ... products that support a physician-driven, collaborative approach to ... patient outcomes.  Wilmot Cancer Institute is a rapidly ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... SAN DIEGO, April 27, 2012 The Centers for ... has quadrupled in a decade to nearly 15,000 in ... South Carolina, the number of people misusing or abusing ... and underscoring the need for access to quality care ...
... /PRNewswire-iReach/ -- SolutionStart, Corp., a leading provider of ... to announce John Karagiannis as its new Vice President ... over 12-years of strong experience in Information Technology having ... Designer, and Analyst providing comprehensive technical and business support ...
Cached Medicine Technology:Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 2Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 3Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 4
(Date:8/4/2015)... , ... August 04, 2015 , ... The results of ... treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were published on ... Ophthalmology. According to the results of the trial, the implant, more commonly known as ...
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years ... their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas ... other. Following the ceremony was a reception, with music by the Moonlight Serenade ...
(Date:8/4/2015)... ... 2015 , ... The Law Offices of Ben C. Martin , based ... Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter lawyer for the ... clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales Practices and Products ...
(Date:8/4/2015)... ... August 04, 2015 , ... Continuing Education Company ... of an interaction simulation session entitled "NOACS: What the Evidence Shows in Managing ... Learning Institute Inc. and EDUmotion US LLC. , This special activity was recently ...
(Date:8/4/2015)... ... , ... Mr Didier Cauchois, CIO of information systems at ... Mr Cauchois attributes the success to the dedication from the team at COL, ... offered by Winscribe's platform. , "We have already begun to see the ...
Breaking Medicine News(10 mins):Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... to a small-scale, in-office, observational study, psychiatrists and ... of pediatric ADHD and psychiatric comorbidities, particularly regarding ... which utilized accepted sociolinguistic methodologies to evaluate the ... presented recently at the 20th annual U.S. Psychiatric ...
... symptoms at least once a week, survey shows , , THURSDAY, ... how well asthma patients in the United States think they ... their daily lives, according to a survey released Thursday by ... of the survey respondents said they have their asthma symptoms ...
... that as HIV treatment improved and as HIV-related public ... disease and seek care, that HIV-infected patients would seek ... are actually sicker when they begin therapy. The study ... Infectious Diseases, currently available online. , The study, carried ...
... 25 Cash Technologies, Inc.,(Amex: TQ ... Claim-Remedi,Services, Inc. has entered into a Services ... to incorporate Claim-Remedi,s products into,TriCap,s ARxChange(TM) debt ... centralized on-line marketplace for the disposition of,healthcare ...
... Developer of Zone Sonography(TM) ... ... Systems,a developer of premium ultrasound systems and proprietary Zone,Sonography(TM) technology, announced ... financial officer (CFO). Marcotte has,more than 20 years of finance and ...
... DENVER, Oct. 25 Medical Simulation Corporation (MSC),announces ... Health,System to provide simulation training and education services ... the system,s,flagship facility, the Hospital of the University ... Report as one of the top 18 hospitals ...
Cached Medicine News:Health News:Psychiatrists, parents significantly differ in ADHD, psychiatric comorbidities perceptions 2Health News:Most Asthmatics Don't Have Illness Under Control 2Health News:Most Asthmatics Don't Have Illness Under Control 3Health News:HIV patients sicker when seeking care than in the past 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With TriCap Health Group 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With TriCap Health Group 3Health News:ZONARE Names Marcotte Chief Financial Officer 2Health News:Medical Simulation Corporation Announces Partnership With University of Pennsylvania Health System 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: